{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T02:50:35Z","timestamp":1782442235371,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00277-023-05309-z","type":"journal-article","created":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T17:01:46Z","timestamp":1688230906000},"page":"2181-2188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impacts of early therapy response, interval to therapy interruption, and cumulative therapy interruption duration on outcome of ibrutinib therapy in relapsed\/refractory chronic lymphocytic leukemia"],"prefix":"10.1007","volume":"102","author":[{"given":"Shenmiao","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7749-8087","authenticated-orcid":false,"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,1]]},"reference":[{"issue":"12","key":"5309_CR1","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1002\/ajh.26367","volume":"96","author":"M Hallek","year":"2021","unstructured":"Hallek M, Al-Sawaf O (2021) Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol 96(12):1679\u20131705","journal-title":"Am J Hematol"},{"issue":"12","key":"5309_CR2","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/ajh.25638","volume":"94","author":"T Munir","year":"2019","unstructured":"Munir T, Brown JR, O\u2019Brien S et al (2019) Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol 94(12):1353\u20131363","journal-title":"Am J Hematol"},{"issue":"3","key":"5309_CR3","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","volume":"34","author":"JA Burger","year":"2020","unstructured":"Burger JA, Barr PM, Robak T et al (2020) Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia 34(3):787\u2013798","journal-title":"Leukemia"},{"issue":"9","key":"5309_CR4","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","volume":"107","author":"C Moreno","year":"2022","unstructured":"Moreno C, Greil R, Demirkan F et al (2022) First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase 3 iLLUMINATE trial. Haematologica 107(9):2108\u20132120","journal-title":"Haematologica"},{"key":"5309_CR5","first-page":"P208","volume":"133196","author":"P Hillmen","year":"2016","unstructured":"Hillmen P, Diels J, Healy N, Iraqi W, Aschan J, Wildgust M (2016) Real-world experience of ibrutinib in >2900 chronic lymphocytic leukemia patients: data from a global named patient program. EHA Library 133196:P208","journal-title":"EHA Library"},{"issue":"35","key":"5309_CR6","doi-asserted-by":"publisher","first-page":"4959","DOI":"10.2217\/fon-2021-0964","volume":"17","author":"JZ Hou","year":"2021","unstructured":"Hou JZ, Ryan K, Du S et al (2021) Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia. Future Oncol 17(35):4959\u20134969","journal-title":"Future Oncol"},{"issue":"15","key":"5309_CR7","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-19-2856","volume":"26","author":"JC Byrd","year":"2020","unstructured":"Byrd JC, Furman RR, Coutre SE et al (2020) Ibrutinib treatment for first-line and relapsed\/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib\/II PCYC-1102 Study. Clin Cancer Res 26(15):3918\u20133927","journal-title":"Clin Cancer Res"},{"issue":"24","key":"5309_CR8","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1002\/(SICI)1097-0258(19961230)15:24<2797::AID-SIM290>3.0.CO;2-V","volume":"15","author":"M Buyse","year":"1996","unstructured":"Buyse M, Piedbois P (1996) On the relationship between response to treatment and survival time. Stat Med 15(24):2797\u20132812","journal-title":"Stat Med"},{"issue":"4","key":"5309_CR9","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/cam4.1337","volume":"7","author":"X Huang","year":"2018","unstructured":"Huang X, Qiu L, Jin J et al (2018) Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study. Cancer Med 7(4):1043\u20131055","journal-title":"Cancer Med"},{"issue":"12","key":"5309_CR10","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D et al (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111(12):5446\u20135456","journal-title":"Blood"},{"issue":"12","key":"5309_CR11","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.3324\/haematol.2016.147900","volume":"101","author":"UC Forum","year":"2016","unstructured":"Forum UC (2016) Ibrutinib for relapsed\/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients. Haematologica 101(12):1563\u20131572","journal-title":"Haematologica"},{"issue":"24","key":"5309_CR12","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1182\/blood-2013-11-538116","volume":"123","author":"P Strati","year":"2014","unstructured":"Strati P, Keating MJ, O\u2019Brien SM et al (2014) Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood 123(24):3727\u20133732","journal-title":"Blood"},{"issue":"11","key":"5309_CR13","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1038\/s41375-018-0132-y","volume":"32","author":"PA Thompson","year":"2018","unstructured":"Thompson PA, Peterson CB, Strati P et al (2018) Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia 32(11):2388\u20132398","journal-title":"Leukemia"},{"issue":"8","key":"5309_CR14","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1038\/s41375-022-01640-y","volume":"36","author":"AM Sigmund","year":"2022","unstructured":"Sigmund AM, Huang Y, Ruppert AS et al (2022) Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib. Leukemia 36(8):2129\u20132131","journal-title":"Leukemia"},{"issue":"21","key":"5309_CR15","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1182\/blood-2017-12-820910","volume":"131","author":"IE Ahn","year":"2018","unstructured":"Ahn IE, Farooqui MZH, Tian X et al (2018) Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood 131(21):2357\u20132366","journal-title":"Blood"},{"issue":"1","key":"5309_CR16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000518398","volume":"145","author":"S Yang","year":"2022","unstructured":"Yang S, Zhu R, Li N et al (2022) Ibrutinib in advanced chronic lymphocytic leukemia\/small lymphocytic lymphoma: lower risk of hepatitis B virus reactivation. Acta Haematol 145(1):54\u201362","journal-title":"Acta Haematol"},{"issue":"11","key":"5309_CR17","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1038\/s41375-022-01699-7","volume":"36","author":"S Yang","year":"2022","unstructured":"Yang S, Kay NE, Shi M, Hanson CA, Gale RP (2022) Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)? Leukemia 36(11):2743\u20132747","journal-title":"Leukemia"},{"issue":"2","key":"5309_CR18","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1182\/blood.2021014960","volume":"140","author":"TD Shanafelt","year":"2022","unstructured":"Shanafelt TD, Wang XV, Hanson CA et al (2022) Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood 140(2):112\u2013120","journal-title":"Blood"},{"key":"5309_CR19","doi-asserted-by":"publisher","unstructured":"Munir T, Moreno C, Owen C et al (2021) First prospective data on minimal residual disease (MRD) outcomes after fixed-duration ibrutinib plus venetoclax (Ibr+Ven) Versus chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of CLL in elderly or unfit patients: the glow study. Blood 138 (Supplement 1):70.\u00a0https:\/\/doi.org\/10.1182\/blood-2021-148666","DOI":"10.1182\/blood-2021-148666"},{"issue":"Supplement 1","key":"5309_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1182\/blood-2022-156070","volume":"140","author":"CU Niemann","year":"2022","unstructured":"Niemann CU, Munir T, Moreno C et al (2022) Residual disease kinetics among patients with high-risk factors treated with first-line fixed-duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): the glow study. Blood 140(Supplement 1):228\u2013230","journal-title":"Blood"},{"key":"5309_CR21","unstructured":"Discontinuation rates due to EAs generally decreased over time (2023) https:\/\/www.imbruvicahcp.com\/cll\/safety\/pooled-long-term-discontinuation-rates. Accessed 12 March 2023"},{"issue":"22","key":"5309_CR22","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1182\/blood.2019896688","volume":"133","author":"IE Ahn","year":"2019","unstructured":"Ahn IE, Basumallik N, Tian X, Soto S, Wiestner A (2019) Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL. Blood 133(22):2452\u20132455","journal-title":"Blood"},{"issue":"19","key":"5309_CR23","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1182\/blood-2016-12-737346","volume":"129","author":"PM Barr","year":"2017","unstructured":"Barr PM, Brown JR, Hillmen P et al (2017) Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL\/SLL. Blood 129(19):2612\u20132615","journal-title":"Blood"},{"issue":"14","key":"5309_CR24","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX et al (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28(14):2381\u20132388","journal-title":"J Clin Oncol"},{"issue":"2","key":"5309_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056813","volume":"8","author":"F Santoleri","year":"2013","unstructured":"Santoleri F, Sorice P, Lasala R, Rizzo RC, Costantini A (2013) Patient adherence and persistence with Imatinib, Nilotinib, Dasatinib in clinical practice. PLoS\u00a0One\u00a08(2):e56813","journal-title":"PLoS ONE"},{"issue":"5","key":"5309_CR26","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/ejh.13499","volume":"105","author":"K Aarup","year":"2020","unstructured":"Aarup K, Rotbain EC, Enggaard L et al (2020) Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib. Eur J Haematol 105(5):646\u2013654","journal-title":"Eur J Haematol"},{"issue":"25","key":"5309_CR27","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM et al (2015) Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 373(25):2425\u20132437","journal-title":"N Engl J Med"},{"issue":"5","key":"5309_CR28","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1158\/1078-0432.CCR-16-1431","volume":"23","author":"SE Coutre","year":"2017","unstructured":"Coutre SE, Furman RR, Flinn IW et al (2017) Extended treatment with single-agent ibrutinib at the 420 mg dose leads to durable responses in chronic lymphocytic leukemia\/small lymphocytic lymphoma. Clin Cancer Res 23(5):1149\u20131155","journal-title":"Clin Cancer Res"},{"issue":"2","key":"5309_CR29","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.mayocpiqo.2019.01.002","volume":"3","author":"JG Le-Rademacher","year":"2019","unstructured":"Le-Rademacher JG, Storrick EM, Jatoi A, Mandrekar SJ (2019) Physician-reported experience and understanding of adverse event attribution in cancer clinical trials. Mayo Clin Proc Innov Qual Outcomes 3(2):176\u2013182","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"3","key":"5309_CR30","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1158\/1078-0432.CCR-15-0339","volume":"22","author":"A Eaton","year":"2016","unstructured":"Eaton A, Iasonos A, Gounder MM et al (2016) Toxicity attribution in Phase I trials: evaluating the effect of dose on the frequency of related and unrelated toxicities. Clin Cancer Res 22(3):553\u2013559","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05309-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05309-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05309-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T07:08:10Z","timestamp":1689232090000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05309-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["5309"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05309-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,1]]},"assertion":[{"value":"1 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RPG is a consultant to BeiGene Ltd., Fusion Pharma LLC, LaJolla NanoMedical Inc., Mingsight Parmaceuticals Inc., CStone Pharmaceuticals, NexImmune Inc., and Prolacta Bioscience; advisor to Antengene Biotech LLC, Medical Director of FFF Enterprises Inc.; partner of AZAC Inc.; Board of Director for Russian Foundation for Cancer Research Support; and Scientific Advisory Board member for StemRad Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}